Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care
- Conditions
- First Posted Date
- 2001-12-21
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 250
- Registration Number
- NCT00028327
- Locations
- 🇺🇸
Beth Israel Med Ctr, New York, New York, United States
🇺🇸Univ of California San Francisco, San Francisco, California, United States
🇺🇸Washington Univ School of Medicine, St Louis, Missouri, United States
Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 110
- Registration Number
- NCT00000923
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, St Louis, Missouri, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
A Study of Zidovudine in HIV-Infected Pregnant Women and Their Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 40
- Registration Number
- NCT00001106
- Locations
- 🇺🇸
UCLA Med Ctr / Pediatric, Los Angeles, California, United States
🇺🇸Univ of Miami (Pediatric), Miami, Florida, United States
🇺🇸Boston City Hosp / Pediatrics, Boston, Massachusetts, United States
An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 50
- Registration Number
- NCT00000709
- Locations
- 🇺🇸
Univ Hosp of Cleveland / Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Tulane Univ School of Medicine, New Orleans, Louisiana, United States
🇺🇸Univ of Rochester Medical Center, Rochester, New York, United States
Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 440
- Registration Number
- NCT00000885
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Division of Inf Diseases/ Indiana Univ Hosp, Indianapolis, Indiana, United States
🇺🇸Boston Med Ctr, Boston, Massachusetts, United States
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 34
- Registration Number
- NCT00000891
- Locations
- 🇺🇸
Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Immunobiology Research Institute
- Registration Number
- NCT00002109
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Fisher Med Group, Phoenix, Arizona, United States
🇺🇸Ctr for Special Immunology, New York, New York, United States
A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 30
- Registration Number
- NCT00001005
- Locations
- 🇺🇸
Duke Univ. Med. Ctr. Adult CRS, Durham, North Carolina, United States
A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 538
- Registration Number
- NCT00001104
- Locations
- 🇺🇸
Univ Hosp of Cleveland / Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States
🇺🇸Hemophilia Ctr of Western PA / Univ of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 390
- Registration Number
- NCT00000814
- Locations
- 🇺🇸
Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States
🇺🇸Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States
🇺🇸Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.